Anhui Fengyuan Pharmaceutical operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Anhui Fengyuan Pharmaceutical with three other
companies in this sector in CHINA :
Haisco Pharmaceutical Group Co Ltd
sales of 3.33 billion Chinese Renmimbi [US$515.99 million]
of which 100%
was Pharmaceutical Industry),
Heilongjiang ZBD Pharmaceutical Co Ltd
(3.33 billion Chinese Renmimbi [US$516.41 million]
of which 66%
was Pharmaceutical Industry), and
Chengdu Kanghong Pharmaceutical Group Co Ltd
(3.30 billion Chinese Renmimbi [US$510.65 million]
of which 100%
was Pharmaceutical Manufacturing).
During the first
quarter of 2021, sales at Anhui Fengyuan Pharmaceutical totalled
856.71 million Chinese Renmimbi.
an increase of 16.2%
from the 737.12 million Chinese Renmimbi in sales at the company during the first quarter of 2020.
During the year ended December of 2020, sales at
Anhui Fengyuan Pharmaceutical were 3.32 billion Chinese Renmimbi (US$514.68 million).
increase of 2.6%
versus 2019, when the company's sales were 3.24 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Anhui Fengyuan Pharmaceutical
(and since 2015, sales have increased a total of 114%).
Sales of Medicine Retail Circulation saw an increase
that was more than double the company's growth rate: sales were up
10.4% in 2020, from
1.53 billion Chinese Renmimbi to 1.69 billion Chinese Renmimbi.
Not all segments of Anhui Fengyuan Pharmaceutical experienced an increase in sales in 2020:
sales of Other Operations fell 7.3% to 58.33 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).
Anhui Fengyuan Pharmaceutical also experienced decreases in sales in
Medicine Manufacturing (down 4.4% to 1.57 billion Chinese Renmimbi)